SCHEMBL13282996

SCHEMBL13282996

CSc1nc2cccc(F)c2c(=O)n1NC(=O)Cc1cccc(F)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.44
TSHR P16473 1/20 0.44
NPSR1 Q6W5P4 1/20 0.43
RAB9A P51151 1/20 0.41
GLS O94925 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MAPT P10636 1/20 0.40
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
PDE7A Q13946 1/20 0.39
PDE7B Q9NP56 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
PRKACA P17612 1/20 0.38
ROCK1 Q13464 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13282986 0.91 NPSR1 (0.47) NPSR1RAB9AGLSL3MBTL1MAPT
SCHEMBL3378668 0.90 NPSR1 (0.45) HTTNPSR1RAB9AL3MBTL1PDE4A
SCHEMBL13283007 0.89 RAB9A (0.44) HTTTSHRNPSR1RAB9AGLS
SCHEMBL3380657 0.87 NPSR1 (0.58) HTTTSHRNPSR1RAB9AL3MBTL1
SCHEMBL13102058 0.85 GLS (0.41) HTTNPSR1GLSL3MBTL1MAPT
SCHEMBL3378917 0.83 NPSR1 (0.56) HTTNPSR1RAB9AL3MBTL1MAPT
SCHEMBL13102401 0.82 GLS (0.39) GLSL3MBTL1MAPTPRKACAROCK1
SCHEMBL13282911 0.82 TRPV4 (0.44) HTTNPSR1RAB9AALDH1A1RXFP1
SCHEMBL13102065 0.81 PDE1C (0.42) TSHRGLSL3MBTL1MAPTPRKACA
SCHEMBL13283034 0.81 NPSR1 (0.48) HTTNPSR1RAB9AL3MBTL1PDE7A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS ICAGEN, INC. (US) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190746-A1 QUINAZOLINONES AS POTASSIUM CHANNEL MODULATORS KCNQ1, KCNK17, KCNQ2 HTT 517/4885TSHR 1412/4885NPSR1 1722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.